Interval breast cancers are not biologically distinct--just more difficult to diagnose
- PMID: 7977992
- DOI: 10.1016/s0002-9610(05)80118-7
Interval breast cancers are not biologically distinct--just more difficult to diagnose
Abstract
Background: Breast cancer diagnosed within 1 year of a negative annual screening examination is called interval breast cancer (IBC) and is considered to be a more virulent subtype of disease.
Methods: We reviewed clinical data on 24 women who were diagnosed as having IBC while participating in the Breast Cancer Detection Demonstration Project at Ellis Fischel Cancer Hospital and the Women's Cancer Control Program screening project in Columbia, Missouri, between 1974 and 1992. We reinterpreted mammograms from the visit prior to the diagnosis of IBC for possible misdiagnosis, changes suggestive of malignancy, and Wolfe's patterns. Archival paraffin blocks from 19 patients were used to determine qualitative expression of tumor markers.
Results: Observed 5-, 8-, and 10-year survival rates were identical to published data for patients with non-IBC. Seventy-four percent of the mammograms evidenced dysplastic Wolfe's patterns (P2 and DY), and one patient was found retrospectively to have shown evidence of cancer which was missed. Compared to breast cancers in general, fewer IBC tumors expressed tumor markers associated with poor prognosis.
Conclusions: Survival rates and tumor marker expressions in this retrospective cohort suggest that IBC tumors are not more biologically aggressive than noninterval tumors. They are more difficult to diagnose both by physical examination and mammography.
Similar articles
-
Interval Breast Cancer Versus Screen-Detected Cancer: Comparison of Clinicopathologic Characteristics in a Single-Center Analysis.Clin Breast Cancer. 2017 Nov;17(7):564-571. doi: 10.1016/j.clbc.2017.04.001. Epub 2017 Apr 11. Clin Breast Cancer. 2017. PMID: 28456487 Clinical Trial.
-
Breast cancer screening by mammography in women aged under 50 years in Japan.Anticancer Res. 2000 Sep-Oct;20(5C):3689-94. Anticancer Res. 2000. PMID: 11268440
-
Facility Mammography Volume in Relation to Breast Cancer Screening Outcomes.J Med Screen. 2016 Mar;23(1):31-7. doi: 10.1177/0969141315595254. Epub 2015 Aug 11. J Med Screen. 2016. PMID: 26265482
-
Survival advantage differences by age. Evaluation of the extended follow-up of the Breast Cancer Detection Demonstration Project.Cancer. 1994 Jul 1;74(1 Suppl):301-10. doi: 10.1002/cncr.2820741315. Cancer. 1994. PMID: 8004601 Clinical Trial.
-
Why diagnosing inflammatory breast cancer is hard and how to overcome the challenges: a narrative review.Chin Clin Oncol. 2021 Dec;10(6):58. doi: 10.21037/cco-21-116. Chin Clin Oncol. 2021. PMID: 35016512 Review.
Cited by
-
A study of interval breast cancer within the NHS breast screening programme.J Clin Pathol. 2000 Feb;53(2):140-6. doi: 10.1136/jcp.53.2.140. J Clin Pathol. 2000. PMID: 10767831 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical